快速检索
年期检索
亚洲社会药学 ›› 2020, Vol. 15 ›› Issue (4): 198-212.
Piao Huiling, Wei Xingchen, Wang Nan, Wang Xing, Zhou Yusheng, Dong Li*
Piao Huiling, Wei Xingchen, Wang Nan, Wang Xing, Zhou Yusheng, Dong Li*
摘要： Objective To explore the impact of the “4+7” city drug centralized procurement policy implemented from April 1st, 2019 on China’s pharmaceutical market and the differences between this pilot scheme and the first volume procurement, so as to put forward some suggestions for this policy and improve the drug price formation mechanism. Methods The characteristics of the “4+7” volume procurement policy and its improvements were summarized through literature research, and the distribution of the winning enterprises in volume procurement was shown by the chart. Then the overall situation of pharmaceutical enterprises in China was analyzed. Results and Conclusion According to the main distribution of enterprises in the alliance region, we can see that the first round of bid-winning enterprises with 25 varieties are mainly distributed in the eastern coastal cities of Jiangsu, Zhejiang, Shandong, and Guangdong, which shows a trend of developing to provinces of Sichuan, Hubei, and Hunan. With the increase of volume procurement inland cities will be included in the future. This pilot scheme of volume procurement is a reform of the entire pharmaceutical industry. It has improved the market structure and promoted the transformation and upgrading of regional medicine representatives. The most important thing is to enable the public to better enjoy the benefits brought by the low-priced drugs. However, for some pharmaceutical enterprises and drug retail industry, it is a challenge. Therefore, it is necessary to improve the policy and strengthen market supervision and management.
